Epigenetics in Alzheimer's Disease

Alzheimer's disease (AD) is a neurodegenerative disease with unknown pathogenesis and complex pathological manifestations. At present, a large number of studies on targeted drugs for the typical pathological phenomenon of AD (A beta) have ended in failure. Although there are some drugs on the market that indirectly act on AD, their efficacy is very low and the side effects are substantial, so there is an urgent need to develop a new strategy for the treatment of AD. An increasing number of studies have confirmed epigenetic changes in AD. Although it is not clear whether these epigenetic changes are the cause or result of AD, they provide a new avenue of treatment for medical researchers worldwide. This article summarizes various epigenetic changes in AD, including DNA methylation, histone modification and miRNA, and concludes that epigenetics has great potential as a new target for the treatment of AD.

Automated summary

Alzheimer's disease is a complex neurodegenerative disease with unknown causes and pathological changes. Targeted drug studies on the typical pathological phenomenon in AD have had high failure rates, and the existing drugs have low efficacy and significant side effects, leading to an urgent need for new treatment strategies. Increasing studies have shown epigenetic changes in AD, providing a new avenue for medical researchers worldwide.